---
title: "Elevated Lipoprotein(a) and Risk of Atrial Fibrillation"
description: "Elevated lipoprotein(a) is associated with an increased risk of atrial fibrillation, partly independent of its effects on atherosclerotic cardiovascular…"
url: "https://magellanlongevity.com/study/d35450575.md"
canonical: "https://magellanlongevity.com/study/d35450575.html"
html: "https://magellanlongevity.com/study/d35450575.html"
type: "study"
study_key: "d35450575"
journal: "J Am Coll Cardiol"
year: 2022
pmid: "35450575"
doi: "10.1016/j.jacc.2022.02.018"
citations: 1
updated: 2026-09-02
author: "Gabriel Radu, DO"
author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765."
publisher: "Magellan Longevity"
content_format: "markdown"
---

# Elevated Lipoprotein(a) and Risk of Atrial Fibrillation

[Home](https://magellanlongevity.com/) › [Research map](https://magellanlongevity.com/longevity-research-map.html) › Elevated Lipoprotein(a) and Risk of Atrial Fibrillation

**HTML version:** https://magellanlongevity.com/study/d35450575.html · **In the Magellan app:** https://magellanlongevity.com/#/study/d35450575

## Citation

| Field | Value |
| --- | --- |
| Journal | J Am Coll Cardiol |
| Year | 2022 |
| PMID | [35450575](https://pubmed.ncbi.nlm.nih.gov/35450575/) |
| DOI | [10.1016/j.jacc.2022.02.018](https://doi.org/10.1016/j.jacc.2022.02.018) |
| Study key | d35450575 |

## Takeaway

Elevated lipoprotein(a) is associated with an increased risk of atrial fibrillation, partly independent of its effects on atherosclerotic cardiovascular disease.

## The question

Does elevated lipoprotein(a) (Lp[a]) increase the risk of atrial fibrillation (AF), and is this association independent of atherosclerotic cardiovascular disease (ASCVD)?

## Hypothesis

The study investigated the role of Lp(a) in AF and whether it is independent of ASCVD.

## Methods

The study analyzed measured and genetically predicted Lp(a) levels in relation to 20,432 cases of incident AF in the UK Biobank (N = 435,579). Mendelian randomization analyses were also conducted using summary-level data for AF from publicly available genome-wide association studies (N = 1,145,375).

## Results

In the UK Biobank, each 50 nmol/L increase in Lp(a) was associated with an increased risk of incident AF (measured Lp[a]: HR: 1.03; genetically predicted Lp[a]: OR: 1.03). Mendelian randomization analyses replicated this effect (OR: 1.04 per 50 nmol/L Lp[a] increase). Only 39% of Lp(a) risk was mediated through ASCVD, suggesting an independent influence on AF.

## Conclusion

The findings suggest that Lp(a) is a potential causal mediator in the development of AF, with effects extending across myocardial tissues and partly independent of its known effects on ASCVD. Ongoing clinical trials for Lp(a)-lowering therapies should evaluate effects on AF prevention.

## Limitations

The abstract does not explicitly state limitations of the study.

## Verbatim from the abstract

> genetically predicted Lp(a) associated with an increased risk of incident atrial fibrillation

## Increased Risk of Atrial Fibrillation per 50 nmol/L Increase in Lp(a)

| Measure | Hazard Ratio / Odds Ratio |
| --- | --- |
| Measured Lp(a) (UK Biobank) | 1.03 |
| Genetically Predicted Lp(a) (UK Biobank) | 1.03 |
| Mendelian Randomization (Independent Data) | 1.04 |

*Each 50 nmol/L increase in Lp(a) was associated with an increased risk of incident AF across different analyses.*

## Where this study is used on Magellan

This paper is one of the citations behind the evidence grade on the pages below. Grades are assigned from the published research and are independent of affiliate commissions.

| Compound or device | Evidence grade | Graded pages |
| --- | --- | --- |
| Lp(a) Mail-In Test | Measurement tool | [Lp(a) Mail-In Test](https://magellanlongevity.com/p/141.md) |

## Reference

1. **Elevated Lipoprotein(a) and Risk of Atrial Fibrillation**
   J Am Coll Cardiol 2022 · [PMID 35450575](https://pubmed.ncbi.nlm.nih.gov/35450575/) · [DOI 10.1016/j.jacc.2022.02.018](https://doi.org/10.1016/j.jacc.2022.02.018)

   > genetically predicted Lp(a) associated with an increased risk of incident atrial fibrillation

## Structured data

```json
{"@context":"https://schema.org","@graph":[{"@type":"MedicalWebPage","@id":"https://magellanlongevity.com/study/d35450575.html#page","url":"https://magellanlongevity.com/study/d35450575.html","name":"Elevated Lipoprotein(a) and Risk of Atrial Fibrillation","description":"Elevated lipoprotein(a) is associated with an increased risk of atrial fibrillation, partly independent of its effects on atherosclerotic cardiovascular…","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/study/d35450575.md"},"dateModified":"2026-09-02"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Research map","item":"https://magellanlongevity.com/longevity-research-map.html"},{"@type":"ListItem","position":3,"name":"Elevated Lipoprotein(a) and Risk of Atrial Fibrillation","item":"https://magellanlongevity.com/study/d35450575.html"}]},{"@type":"ScholarlyArticle","@id":"https://magellanlongevity.com/study/d35450575.html#study","name":"Elevated Lipoprotein(a) and Risk of Atrial Fibrillation","headline":"Elevated Lipoprotein(a) and Risk of Atrial Fibrillation","datePublished":"2022","isPartOf":{"@type":"Periodical","name":"J Am Coll Cardiol"},"identifier":"PMID:35450575","url":"https://pubmed.ncbi.nlm.nih.gov/35450575/","sameAs":"https://doi.org/10.1016/j.jacc.2022.02.018","abstract":"Elevated lipoprotein(a) is associated with an increased risk of atrial fibrillation, partly independent of its effects on atherosclerotic cardiovascular disease."}]}
```

## Related on Magellan Longevity

- [Lp(a) Mail-In Test](https://magellanlongevity.com/p/141.md) — product graded on this and related evidence
- [Evidence: Lipoprotein(a) concentration](https://magellanlongevity.com/study/s141.md)
- [Lipoprotein(a) and Cardiovascular Disease](https://magellanlongevity.com/study/d33236085.md)
- [Longevity research map](https://magellanlongevity.com/longevity-research-map.html)
- [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md)

## Scope and disclosures

Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication.

Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases.

Reviewed for accuracy by a board-certified physician (DO).